Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STOP BLOQ: Surveillance and Treatment to Prevent Fetal Atrioventricular Block
NCT04474223Phase 3Active, not recruiting
- Sponsor
- NYU Langone Health
- Start
- Aug 2020
- Primary completion
- Dec 2028
- Modality
- Recombinant Proteins and Enzymes, Orthosteric Ligands
- Countries
- 2
01
Overview
A Phase 3 trial of dexamethasone, intravenous immunoglobulin G in Atrioventricular Block (AVB), sponsored by NYU Langone Health. Started Aug 2020; status: active, not recruiting.
02
Drugs
dexamethasoneintravenous immunoglobulin G
03
Conditions
Atrioventricular Block (AVB)
Beyond the preview
Go deeper on NCT04474223.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04474223.